ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that on October 20, 2022, it received a Notice of Allowance for ABV-1504 from the US Patent and Trademark Office.
The patent, entitled “Polygala Extract for the Treatment of Major Depressive Disorder,” outlines a method for treating major depressive disorder by oral administration of a composition, ABV-1504, containing Radix Polygalae (Polygala tenuifolia Willd). The polygala extract, designated PDC-1421, is the key active ingredient in ABV-1504 which was orally administered to healthy volunteers and proved to be safe and well-tolerated for a daily dose from 380 mg to 3800 mg. The study indicated that the drug can be administered chronically over at least 25 days with the daily dose administered once per day, twice per day, or three times per day, wherein each dose contains from 380 mg to 760 mg of the botanical extraction.
https://finance.yahoo.com/news/abvc-biopharma-receives-notice-allowance-133000252.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.